| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
British Medical Bulletin 57:61-79 (2001)
© 2001 Oxford University Press
Depression – emerging insights from neurobiology
*Department of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, India
Department of Psychiatry and Pharmacology, Yale University, Connecticut Mental Health Center, New Haven, Connecticut, USA
An emerging hypothesis suggests that the pathogenesis and treatment of depression is likely to involve a plasticity of neuronal pathways. The inability of neuronal systems to exhibit appropriate, adaptive plasticity could contribute to the pathogenesis of depression. Antidepressant treatments may exert their therapeutic effects by stimulating appropriate adaptive changes in neuronal systems. Recent studies have demonstrated that chronic antidepressant administration up-regulates the cAMP signal transduction cascade resulting in an increased expression and function of the transcription factor CREB. Enhanced CREB expression leads to an up-regulation of specific target genes, including the neurotrophin BDNF. Chronic antidepressant treatments enhance BDNF expression within hippocampal and cortical neurons and can prevent the stress-induced decrease in BDNF expression. Stress has been shown to: (i) induce neuronal atrophy/death; and (ii) decrease neurogenesis of hippocampal neurons. Clinical studies indicate significant hippocampal damage in cases of major, recurrent depression. It is possible that antidepressant treatments through enhanced expression of growth and survival promoting factors like BDNF may prevent or reverse the atrophy and damage of hippocampal neurons. Indeed, studies have indicated that chronic antidepressant treatments enhance hippocampal neurogenesis, promote neuronal sprouting and prevent atrophy. The molecular mechanisms underlying the effects of antidepressant treatments including adaptations in the cAMP transduction cascade, CREB and BDNF gene expression, and structural neuronal plasticity are discussed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. S. Mayberg, A. M. Lozano, V. Voon, H. E. McNeely, D. Seminowicz, C. Hamani, J. M. Schwalb, and S. H. Kennedy Deep Brain Stimulation for Treatment-Resistant Depression Focus, January 1, 2008; 6(1): 143 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Benedetti, H. S. Mayberg, T. D. Wager, C. S. Stohler, and J.-K. Zubieta Neurobiological Mechanisms of the Placebo Effect J. Neurosci., November 9, 2005; 25(45): 10390 - 10402. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gask Is depression a chronic illness? For the motion Chronic Illness, June 1, 2005; 1(2): 101 - 106. [PDF]
|
|
|
|
 |
|
 D. A. Bennett, R. S. Wilson, J. A. Schneider, J. L. Bienias, and S. E. Arnold Cerebral Infarctions and the Relationship of Depression Symptoms to Level of Cognitive Functioning in Older Persons Am J Geriatr Psychiatry, April 1, 2004; 12(2): 211 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Wood, L. T. Young, L. P. Reagan, B. Chen, and B. S. McEwen Stress-induced structural remodeling in hippocampus: Prevention by lithium treatment PNAS, March 16, 2004; 101(11): 3973 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S Mayberg Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment Br. Med. Bull., March 1, 2003; 65(1): 193 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. MAYBERG, J. A. SILVA, S. K. BRANNAN, J. L. TEKELL, R. K. MAHURIN, S. McGINNIS, and P. A. JERABEK Dr. Mayberg and Colleagues Reply Am J Psychiatry, February 1, 2003; 160(2): 390 - 391. [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Zaman, R. Zaman, I. Reid, and C. Stewart Long-term potentiation and changes seen in depression Authors' reply The British Journal of Psychiatry, December 1, 2001; 179 (6): 559 - 560. [Full Text]
|
|